Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 6/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.53 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829343 | 0.86 | RPS6KA5 (0.49) | DYRK1ACCNT1CCNA2CDK2CDK9 | |
| SCHEMBL4298090 | 0.84 | DYRK1A (0.53) | NTRK1DYRK1APIK3CANEK1CCNT1 | |
| SCHEMBL4831176 | 0.81 | DYRK1A (0.39) | DYRK1AKITAXLCDK8TNIK | |
| SCHEMBL8290894 | 0.80 | RPS6KA5 (0.45) | NTRK1DYRK1ACDK9KITCDK8 | |
| SCHEMBL4829524 | 0.79 | NTRK1 (0.42) | NTRK1DYRK1ANEK1KITAXL | |
| SCHEMBL4831547 | 0.77 | DYRK1A (0.56) | NTRK1DYRK1APIK3CANEK1CDK2 | |
| SCHEMBL4831120 | 0.76 | RPS6KA5 (0.50) | DYRK1ACCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8290891 | 0.76 | IKBKE (0.35) | DYRK1ACDK2CDK9PDPK1CDK8 | |
| SCHEMBL4827380 | 0.73 | NTRK1 (0.50) | NTRK1PIK3CANEK1CCNT1CCNA2 | |
| SCHEMBL4827652 | 0.73 | NEK1 (0.45) | NTRK1DYRK1APIK3CANEK1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K6 | NTRK1 1926/4885DYRK1A 832/4885PIK3CA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.